Concepts (187)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antibodies, Neutralizing | 22 | 2024 | 285 | 3.330 |
Why?
|
| HIV Antibodies | 15 | 2021 | 243 | 2.790 |
Why?
|
| HIV-1 | 16 | 2024 | 1239 | 1.810 |
Why?
|
| Antibodies, Viral | 8 | 2024 | 266 | 1.170 |
Why?
|
| Spike Glycoprotein, Coronavirus | 11 | 2024 | 84 | 1.130 |
Why?
|
| Humans | 55 | 2024 | 14077 | 0.980 |
Why?
|
| HIV Infections | 20 | 2024 | 4946 | 0.920 |
Why?
|
| Neutralization Tests | 10 | 2024 | 106 | 0.910 |
Why?
|
| Epitopes | 8 | 2021 | 97 | 0.900 |
Why?
|
| AIDS Vaccines | 9 | 2021 | 150 | 0.860 |
Why?
|
| Immune Evasion | 6 | 2022 | 31 | 0.860 |
Why?
|
| HIV Envelope Protein gp120 | 6 | 2018 | 104 | 0.850 |
Why?
|
| Superinfection | 2 | 2018 | 8 | 0.670 |
Why?
|
| Mutation | 8 | 2024 | 299 | 0.620 |
Why?
|
| RNA, Viral | 2 | 2018 | 303 | 0.610 |
Why?
|
| Cross Reactions | 4 | 2024 | 44 | 0.600 |
Why?
|
| B-Lymphocytes | 6 | 2021 | 33 | 0.580 |
Why?
|
| Respiratory Syncytial Virus, Human | 3 | 2024 | 137 | 0.560 |
Why?
|
| Peptide Fragments | 2 | 2018 | 36 | 0.550 |
Why?
|
| Phylogeny | 5 | 2024 | 231 | 0.540 |
Why?
|
| Pandemics | 5 | 2023 | 280 | 0.460 |
Why?
|
| South Africa | 20 | 2024 | 7312 | 0.410 |
Why?
|
| Genome, Viral | 5 | 2024 | 64 | 0.410 |
Why?
|
| Immunity, Humoral | 2 | 2024 | 42 | 0.400 |
Why?
|
| Animals | 9 | 2022 | 1063 | 0.390 |
Why?
|
| Epidemiological Monitoring | 2 | 2022 | 45 | 0.390 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 2 | 2024 | 36 | 0.380 |
Why?
|
| Adjuvants, Immunologic | 2 | 2021 | 21 | 0.370 |
Why?
|
| Hospitalization | 3 | 2022 | 392 | 0.360 |
Why?
|
| Antibody Formation | 2 | 2021 | 61 | 0.360 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 3 | 2021 | 49 | 0.350 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2024 | 176 | 0.350 |
Why?
|
| Evolution, Molecular | 4 | 2024 | 60 | 0.330 |
Why?
|
| Antibodies, Monoclonal | 2 | 2021 | 137 | 0.300 |
Why?
|
| Genomics | 3 | 2023 | 106 | 0.280 |
Why?
|
| Adult | 12 | 2024 | 5664 | 0.280 |
Why?
|
| Female | 13 | 2024 | 8751 | 0.250 |
Why?
|
| Nanoparticles | 3 | 2021 | 104 | 0.240 |
Why?
|
| T-Lymphocytes | 2 | 2022 | 59 | 0.240 |
Why?
|
| Phylogeography | 2 | 2021 | 15 | 0.230 |
Why?
|
| Signal Transduction | 1 | 2024 | 33 | 0.230 |
Why?
|
| Receptors, IgG | 1 | 2024 | 28 | 0.230 |
Why?
|
| Severity of Illness Index | 2 | 2022 | 243 | 0.230 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2024 | 47 | 0.220 |
Why?
|
| Middle Aged | 8 | 2024 | 3425 | 0.220 |
Why?
|
| Protein Engineering | 2 | 2020 | 7 | 0.220 |
Why?
|
| Intention | 1 | 2023 | 23 | 0.220 |
Why?
|
| Genetic Variation | 3 | 2024 | 169 | 0.210 |
Why?
|
| Peptides | 2 | 2020 | 40 | 0.210 |
Why?
|
| Models, Molecular | 5 | 2022 | 84 | 0.210 |
Why?
|
| Immunization | 2 | 2020 | 63 | 0.210 |
Why?
|
| Viruses | 1 | 2023 | 47 | 0.210 |
Why?
|
| Prospective Studies | 5 | 2024 | 1131 | 0.200 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2021 | 145 | 0.200 |
Why?
|
| Seroepidemiologic Studies | 4 | 2023 | 104 | 0.200 |
Why?
|
| Lymph | 1 | 2021 | 1 | 0.200 |
Why?
|
| Saponins | 1 | 2021 | 1 | 0.200 |
Why?
|
| Toll-Like Receptors | 1 | 2021 | 1 | 0.200 |
Why?
|
| Immunity, Cellular | 1 | 2022 | 25 | 0.200 |
Why?
|
| Adaptive Immunity | 1 | 2021 | 4 | 0.200 |
Why?
|
| Terminology as Topic | 1 | 2021 | 10 | 0.190 |
Why?
|
| Hospital Mortality | 1 | 2021 | 94 | 0.180 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2021 | 91 | 0.180 |
Why?
|
| Plants, Genetically Modified | 1 | 2020 | 3 | 0.180 |
Why?
|
| Sequence Analysis, RNA | 2 | 2021 | 17 | 0.170 |
Why?
|
| Aluminum Hydroxide | 1 | 2020 | 1 | 0.170 |
Why?
|
| Tobacco | 1 | 2020 | 14 | 0.170 |
Why?
|
| Macaca mulatta | 4 | 2021 | 14 | 0.170 |
Why?
|
| Germinal Center | 1 | 2019 | 3 | 0.170 |
Why?
|
| Influenza Vaccines | 1 | 2021 | 132 | 0.170 |
Why?
|
| Amino Acid Sequence | 5 | 2019 | 139 | 0.170 |
Why?
|
| HIV | 3 | 2023 | 380 | 0.160 |
Why?
|
| Lysine | 1 | 2018 | 5 | 0.160 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2018 | 8 | 0.160 |
Why?
|
| Introns | 1 | 2018 | 13 | 0.160 |
Why?
|
| Exons | 1 | 2018 | 17 | 0.160 |
Why?
|
| Vaccines | 1 | 2019 | 84 | 0.150 |
Why?
|
| Influenza, Human | 1 | 2021 | 360 | 0.140 |
Why?
|
| Binding Sites, Antibody | 1 | 2017 | 8 | 0.140 |
Why?
|
| HIV Antigens | 1 | 2017 | 26 | 0.140 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2017 | 28 | 0.140 |
Why?
|
| Africa | 3 | 2022 | 360 | 0.130 |
Why?
|
| Antigenic Variation | 1 | 2015 | 7 | 0.130 |
Why?
|
| Male | 6 | 2024 | 6489 | 0.130 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 1377 | 0.110 |
Why?
|
| Molecular Sequence Data | 4 | 2015 | 263 | 0.110 |
Why?
|
| HIV Envelope Protein gp160 | 1 | 2014 | 22 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2024 | 939 | 0.110 |
Why?
|
| Aged | 3 | 2023 | 1650 | 0.110 |
Why?
|
| Epitope Mapping | 3 | 2019 | 31 | 0.100 |
Why?
|
| Polysaccharides | 1 | 2012 | 45 | 0.100 |
Why?
|
| World Health Organization | 2 | 2023 | 134 | 0.100 |
Why?
|
| Child | 3 | 2022 | 2180 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 2 | 2021 | 11 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 12 | 0.090 |
Why?
|
| Double-Blind Method | 2 | 2022 | 263 | 0.090 |
Why?
|
| Adolescent | 3 | 2023 | 2858 | 0.090 |
Why?
|
| CD4 Antigens | 3 | 2017 | 47 | 0.090 |
Why?
|
| Glycosylation | 2 | 2021 | 17 | 0.080 |
Why?
|
| Lymphocyte Activation | 2 | 2020 | 40 | 0.080 |
Why?
|
| Vaccination | 2 | 2023 | 347 | 0.080 |
Why?
|
| Antibody Affinity | 2 | 2018 | 11 | 0.070 |
Why?
|
| Complementarity Determining Regions | 2 | 2017 | 11 | 0.060 |
Why?
|
| Young Adult | 2 | 2022 | 2357 | 0.060 |
Why?
|
| Immunocompromised Host | 1 | 2024 | 33 | 0.060 |
Why?
|
| HIV Seropositivity | 2 | 2019 | 263 | 0.060 |
Why?
|
| Antibody Specificity | 2 | 2013 | 30 | 0.050 |
Why?
|
| Australia | 1 | 2023 | 46 | 0.050 |
Why?
|
| United States | 1 | 2023 | 129 | 0.050 |
Why?
|
| Laboratories | 1 | 2023 | 44 | 0.050 |
Why?
|
| Amino Acids | 1 | 2022 | 16 | 0.050 |
Why?
|
| Placebo Effect | 1 | 2022 | 1 | 0.050 |
Why?
|
| Convalescence | 1 | 2022 | 2 | 0.050 |
Why?
|
| Pregnant Women | 1 | 2022 | 89 | 0.050 |
Why?
|
| Information Storage and Retrieval | 1 | 2022 | 13 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2024 | 654 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2022 | 17 | 0.050 |
Why?
|
| RNA | 1 | 2022 | 26 | 0.050 |
Why?
|
| Botswana | 1 | 2022 | 24 | 0.050 |
Why?
|
| Rats, Wistar | 1 | 2021 | 13 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2022 | 46 | 0.050 |
Why?
|
| Recombination, Genetic | 1 | 2022 | 27 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2022 | 103 | 0.050 |
Why?
|
| Hospitals, Public | 1 | 2022 | 44 | 0.050 |
Why?
|
| Cryoelectron Microscopy | 1 | 2021 | 2 | 0.050 |
Why?
|
| Cell Line | 1 | 2021 | 92 | 0.050 |
Why?
|
| Rats | 1 | 2021 | 130 | 0.050 |
Why?
|
| Protein Conformation | 1 | 2021 | 24 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2022 | 132 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2022 | 171 | 0.050 |
Why?
|
| Mice | 1 | 2021 | 134 | 0.050 |
Why?
|
| Genetic Fitness | 1 | 2021 | 7 | 0.050 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2022 | 59 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 34 | 0.050 |
Why?
|
| Vaccine Potency | 1 | 2021 | 16 | 0.050 |
Why?
|
| Selection, Genetic | 1 | 2021 | 31 | 0.050 |
Why?
|
| Blood Donors | 1 | 2021 | 19 | 0.050 |
Why?
|
| Molecular Typing | 1 | 2021 | 12 | 0.050 |
Why?
|
| Datasets as Topic | 1 | 2021 | 15 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 235 | 0.050 |
Why?
|
| Logistic Models | 1 | 2022 | 252 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2023 | 247 | 0.050 |
Why?
|
| Communication | 1 | 2021 | 56 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2021 | 39 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 40 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2021 | 175 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 90 | 0.040 |
Why?
|
| Learning | 1 | 2020 | 12 | 0.040 |
Why?
|
| Biotechnology | 1 | 2020 | 4 | 0.040 |
Why?
|
| Genetic Engineering | 1 | 2020 | 7 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2020 | 10 | 0.040 |
Why?
|
| Global Health | 1 | 2021 | 183 | 0.040 |
Why?
|
| Phosphoserine | 1 | 2020 | 1 | 0.040 |
Why?
|
| Antigen Presentation | 1 | 2020 | 6 | 0.040 |
Why?
|
| Antigens | 1 | 2020 | 11 | 0.040 |
Why?
|
| Endocytosis | 1 | 2020 | 6 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2020 | 13 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2020 | 15 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2019 | 5 | 0.040 |
Why?
|
| Incidence | 1 | 2022 | 655 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2019 | 24 | 0.040 |
Why?
|
| Time Factors | 1 | 2021 | 503 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2022 | 867 | 0.040 |
Why?
|
| Prevalence | 1 | 2022 | 1149 | 0.040 |
Why?
|
| Protein Binding | 1 | 2018 | 62 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2018 | 17 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2018 | 37 | 0.040 |
Why?
|
| Alleles | 1 | 2018 | 134 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 45 | 0.040 |
Why?
|
| Tenofovir | 1 | 2018 | 158 | 0.040 |
Why?
|
| Rural Population | 1 | 2021 | 624 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2022 | 1675 | 0.040 |
Why?
|
| Crystallography, X-Ray | 1 | 2017 | 12 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2017 | 15 | 0.040 |
Why?
|
| Risk Factors | 1 | 2021 | 1431 | 0.030 |
Why?
|
| Pregnancy | 1 | 2022 | 1815 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 70 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 72 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2015 | 19 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 180 | 0.030 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 1 | 2014 | 4 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2014 | 4 | 0.030 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2014 | 7 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 22 | 0.030 |
Why?
|
| Binding Sites | 1 | 2014 | 43 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2012 | 14 | 0.030 |
Why?
|
| Anti-HIV Agents | 1 | 2018 | 1275 | 0.020 |
Why?
|